Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization (Q24318411)

GOA release 2020-03-11

4

Klaus Pfizenmaier

0 references

author name string

Nicole Müller

1

0 references

Agnes Wyzgol

2

0 references

Sabine Münkel

3

0 references

Harald Wajant

The TNF and TNF receptor superfamilies: integrating mammalian biology

5

0 references

language of work or name

English

0 references

publication date

May 2008

0 references

published in

FEBS Journal

0 references

volume

275

0 references

page(s)

2296-304

0 references

issue

9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Co-stimulatory agonists as immunological adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Costimulation of T cells by OX40, 4-1BB, and CD27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Insights into programmed cell death through structural biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

The molecular architecture of the TNF superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

A Fas agonist induces high levels of apoptosis in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

7 January 2021

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

7 January 2021

Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

7 January 2021

Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

7 January 2021

The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

7 January 2021

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

7 January 2021

OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2008.06382.X

7 January 2021